Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million
Bitget2026/10/07 12:32Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million. The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia. Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans. Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9841089) on October 07, 2026, and is solely responsible for the information contained therein.
- Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million.
- The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia.
- Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans.
- Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bailey speech: Too early to form strong views on the strength of 2nd round effects
15.49 trillion! BlackRock's assets under management have reached half of the US GDP
BlackRock recorded net inflows of $205 billions in the third quarter, with revenue rising 19% year-on-year to $7.75 billions. The flagship iShares ETF attracted more than $135 billions, while net inflows for private credit increased by $5 billions quarter-on-quarter. CEO Larry Fink stated that the company is entering the fourth quarter with accelerating momentum and solid reserves in the private market and pension fund businesses. However, Moody's warned that risks are still accumulating in the private credit market under the high interest rate environment.
The address associated with the Worldcoin project deposited 14.475 million WLD to an exchange within 24 hours.
Crypto prices
More
